Financials in USD. Standardized financial statements.
A compact view of how Ensysce Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M | $3.93M | $1.76M | $0 | $0 |
| Revenue Growth? | -2.8% | +133.5% | -11.6% | -28.5% | -10.2% | +122.9% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $7.22M | $7.59M | $19.84M | $151 | $201 | $3.40M | $1.56M | $0 |
| Gross Profit? | $0 | -$2.01M | -$5.36M | -$17.31M | $3.53M | $3.93M | -$1.64M | -$1.56M | $0 |
| Gross Margin? | 0.0% | -38.6% | -240.1% | -686.1% | +100.0% | +100.0% | -92.9% | 0.0% | 0.0% |
| Operating Expenses? | $10.24M | $4.72M | $5.36M | $6.91M | $23.40M | $5.54M | $6.93M | -$600,000 | $146,695 |
| Operating Income? | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M | -$1.61M | -$8.57M | -$959,000 | -$147,000 |
| EBITDA? | -$10.15M | -$6.73M | -$10.72M | -$24.22M | -$25.93M | $834,821 | -$8.57M | $2.68M | -$27,555 |
| Income Before Tax | -$10.18M | -$7.99M | -$10.63M | -$24.21M | -$29.15M | -$160,875 | -$10.10M | $2.68M | -$27,558 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $553,916 | $3,635 |
| Net Income? | -$10.18M | -$7.99M | -$10.61M | -$24.17M | -$29.08M | $56,770 | -$10.10M | -$1.34M | -$31,193 |
| EPS? | $-3.98 | $-4.57 | $-4.69 | $-139.44 | $-355.68 | $0.56 | $0.24 | $-0.22 | $-0.01 |
| Diluted EPS? | $-3.98 | $-4.57 | $-4.69 | $-139.44 | $-355.68 | $0.56 | $0.24 | $-0.22 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality